Psychiatry

Our psychiatric pipeline features novel combination drug therapies to address the significant shortcomings of current treatment approaches

ProgramIndicationPhase IPhase IIPhase IIPhase IMilestone
ELE-Ket+Adjunctive Treatment of Major Depressive Disorder
Phase I/II Initiation
Q4 2021
ELE-Psilo+Adjunctive Treatment of Major Depressive Disorder
Phase I/II Initiation
Q1 2022

Beyond Psychiatry

Our pipeline of drug candidates extends beyond psychiatry, and includes promising preclinical and clinical-stage drug candidates which harness the anti-inflammatory and disease modifying potential of targeted serotonin 5-HT2A receptor therapies

ProgramIndicationPhase IPhase IIPhase IIPhase INext Milestone
ELE-02Ocular Inflammation
Phase I Initiation
Q1 2023
ELE-LSDAlzheimer’s Disease
Phase Ib Exploratory Study
Q4 2021
ELE-XXPeripheral Inflammatory DiseaseDiscoveryLead Candidate Identification
Q4 2021

Eleusis is a life science company based in London and New York, dedicated to transforming psychedelics into medicines

General & Media Inqueries

contact@eleusisltd.com

Careers Opportunities

careers@eleusisltd.com

London

New York